A company that specializes in the development of nutraceuticals and one-of-a-kind health products has just filed an international cannabis/botanical patent.

The company’s name is CanaQuest and its most recent move in the cannabis industry was made possible, thanks to a sponsored research program at a Canadian educational institute – Ontario’s Western University in London.

What did they patent, you ask? Mentabinol™ – a cannabis-containing formulation developed to treat psychiatric disorders.

“We are very excited by this unique discovery. Reducing the negative side effects of THC is an important step forward in developing more effective cannabinoid therapeutics,” said Western University’s Dr. Steven Laviolette.

Patent-pending Mentabinol™ contains the cannabis plant’s psychoactive element

Mentabinol™ is a unique formulation containing Food Grade Botanical Extract “BX”. The cannabis plant is used to produce the patent-pending product, which is enriched with plant-extracted THC oil.

Numerous preclinical trials have taken place at Western University to explore the benefits of Mentabinol™ applications in the medical field. Scientists discovered that CanaQuest’s medical cannabis solution was successfully capable of minimizing the symptoms of schizophrenia and depression.

In addition to this, it accomplished complete blockage of memory impairment and hyperactive activity, thus indicating its versatility as a treatment for widespread medical conditions like ADHD and Alzheimer’s disease. 

Results of these preclinical trials also suggest the potential of using Mentabinol™ to prevent gene vulnerability, These conclusions were drawn up by a research team at the University fronted by Dr. Steven Laviolette; the university’s lead scientist responsible for heading two of CanaQuest’s sponsored research programs.

“Our Patent is the foundation for real scientifically backed medical cannabis treatment for patients in need,” said the co-founder and President of CanaQuest, Paul Ramsay.

Who is CanaQuest Medical Corp?

The company is committed to studying and developing a one-of-a-kind range of nutraceuticals and health products that contain natural substances, such as cannabis, hemp and algae.

“Our research is focused on the use of cannabis in the context of cancer and the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder (PTSD),” reads an official statement from the company.

Currently, CanaQuest is collaborating with two research universities to explore the pharmaceutical potential of treating patients with cannabis oil extract and botanical extracts.

CanaQuest’s patent-pending Mentabinol™ deemed to be a “game-changer”

Following the completion of their studies, CanaQuest’s team of researchers affirmed that the cannabis plant possesses plenty of therapeutic potential as a treatment for mental and physical ailments.

Patent-pending Mentabinol™ has been dubbed a “game-changer” by consumers who tried the product. As time progresses, more healthcare physicians and doctors will become aware of this cannabis-based treatment and how to use it safely, due to its psychoactive composition.

All of the company’s clinical trials on animals have been finalized, with human studies expected to commence imminently. The patent is the first in the company’s Master Platform of intellectual property in this field of medicine. CanaQuest is the sole owner of the patent-pending Mentabinol™.